CTLA4 and neoplasm: At present, although no single immunological or tumor-related factor has been found to solely determine the response to an immunotherapeutic agent [29], the expression of CTLA-4 in the tumor or TILs may represent a target, and CTLA-4 blockade may provide therapeutic benefits for NPC.